November 3, 2026 · Mayo Clinic proceedings · DOI: 10.1016/j.mayocp.2026.10.021

The Future Burden of Type 2 Diabetes and the Role of Glycaemic Control and GLP1-RAs.

Listen to this summary

This study used a UK system dynamics model to project the burden of type 2 diabetes from 2024 to 2060, asking how achieving glycaemic targets, with and without population-wide GLP-1 receptor agonist use, would affect prevalence, costs, and complications. Glycaemic control alone was projected to save about £61.4bn, while adding GLP-1 RA cardiorenal benefits raised cumulative savings to about £140.7bn, preventing roughly 4.5 times as many macrovascular complications and 6 times as many deaths. The authors conclude that the cardiorenal protection from GLP-1 RAs provides substantial economic and health value beyond glycaemic control alone.

Melanie Davies, Thomas E Padgett, Scott Goulden, Phil McEwan, Barrie Chubb, Joseph Whitaker, Kamlesh Khunti

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play